
PROGRAM MENU
EDUCATIONAL PROGRAM
WORKSHOPS & SYMPOSIA
CONTINUING EDUCATION
Educational Program
THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.
Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.
Thursday, October 29th
10:00 - 11:30 AM
|
PLENARY 3: ENSURING AND PROMOTING BEST CARE Chair/Organizer: Robert Sidonio, Cathy Hayward
Virtual Room 1 This Plenary will provide unique, expert perspectives on the challenges of ensuring that the best care is provided to persons with thrombosis or bleeding problems. The speakers will touch on broad issues that influence the quality of care, from choices between treatments to advocacy and health promotion. |
||||
1 |
Promoting Patient Safety Jesse Roach. Centers for Medicare and Medicaid Services |
|||||
2 |
Choosing Between New And Old Therapies For Thrombosis Stephan Moll. Unviersity of North Carolina School of Medicine |
|||||
3 |
Ensuring The Best Care For Patients With Congenital And Acquired Bleeding Problems. What Are Our Challenges Len Valentino. National Hemophilia Foundation |
|||||
12:15 - 1:15 PM
|
CORPORATE LUNCH SYMPOSIUM: PFIZER MEDICAL SYMPOSIUM: PERSPECTIVES ON HEMOPHILIA B CARE IN AN ERA OF ADVANCED THERAPEUTICS AND EXTRAVASCULAR FIX SCIENCE: PAST, PRESENT AND FUTURE CONSIDERATIONS
Virtual Room 2 Sponsored By: Pfizer The field of hemophilia has rapidly evolved over the last decade, with a plethora of treatment options currently available, and in clinical development. Historically, the management of hemophilia B has been largely extrapolated from our scientific and clinical understanding of hemophilia A. However, a renewed focus on research in hemophilia B is changing our understanding of the science underpinning this disease and further expanding possibilities for these patients. In this era of rapidly evolving science and technology, it is important to reflect on current management strategies for people with hemophilia B, to support the preservation of joint function and optimize the potential offered by future approaches to care. Our satellite symposium will explore mechanisms for advancing the care of people with hemophilia B in this era of advanced therapeutics. Through discussing the role of real-world data, and our expanding understanding of the science of hemophilia B, we will explore how this progress is driving innovation and resetting our expectations of standards of care. SESSION HANDOUTS Save the Date Flyer Symposium Program Booklet |
||||
| |
CORPORATE LUNCH SYMPOSIUM: PROVEN BLEED PROTECTION WITH EXTENDED FACTOR IX DOSING: LEARN MORE ABOUT THE EXTENSION STUDIES
Virtual Room 1 Sponsored By: CSL Behring Join us as we discuss NEW published data from two extension studies, affirming long-lasting efficacy with up to 4 years of evaluating adult and adolescent patients treated prophylactically at both 7- and 14-day extended intervals. |
||||
2:00 - 3:30 PM
|
NEW INSIGHTS ON MECHANISMS Chair/Organizer: Anne Rose, Rodney Camire
Virtual Room 3 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
||||
Advances in Understanding the Cofactor Function of Factor V Rodney Camire. University of Pennsylvania/Children's Hospital of Philadelphia |
||||||
Update on the interplay between coagulation and complement systems Edward Conway. University of British Columbia Centre for Blood Research |
||||||
Understanding The Clot From Studies Of Fibrin And Factor XIII JW Weisel. University of Pennsylvania |
||||||
NEW STRATEGIES IN HEMOPHILIA THERAPY Chair/Organizer: Michael Recht, Shannon Jackson
Virtual Room 2 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
|||||
1 |
Challenging Bleeding Events In Patients On Novel Hemophilia Therapies Glaivy Batsuli. Emory University a Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta |
|||||
2 |
Tolerance In The Age Of Non-factor Replacement Therapy Shannon Meeks. Emory University/Children's Healthcare of Atlanta |
|||||
3 |
How New Therapies Are Impacting Hemophilia Treatment Centers Jim Munn. Michigan Medicine |
|||||
STARTING AND STOPPING DOACS Chair/Organizer: Arthur Allen, Pall Onunderson
Virtual Room 1 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
|||||
1 |
Planned Interruption of DOAC Therapy James Douketis. McMaster University |
|||||
2 |
Emergency Reversal Of DOAC Therapy: Current Evidence On Best Approaches Deb Siegal. McMaster University |
|||||
3 |
Laboratory Support For Patients On DOAC Therapy: Challenges To Checking For Drug And Measuring Levels Adam Cuker. University of Pennsylvania |
|||||
4:15 - 5:45 PM
|
EVALUATING FOR BLEEDING DISORDERS: WHAT TO DO AFTER THE PATIENT WALKS THROUGH YOUR DOOR Chair/Organizer: Stacy Croteau, Maria Santaella
Virtual Room 2 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
||||
1 |
Bleeding assessment: Key issues for patient evaluation for clinical practice and research across the age spectrum. Sarah O'Brien. |
|||||
2 |
Overview on the laboratory assessment of patients referred for bleeding problems. Cathy Hayward. McMaster University, Hamilton Regional Laboratory Medicine Program |
|||||
3 |
Nursing perspectives on the needs of patients with bleeding problems, with consideration of their quality of life. Christine Guelcher. Children's National Hospital |
|||||
NEW INSIGHTS ON PLATELETS AND THEIR FUNCTIONS Chair/Organizer: A. Koneti Rao, Jorge DiPaola
Virtual Room 3 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
|||||
1 |
Platelet Thiol Isomerases: Bench To Bedside Robert Flaumerhaft. |
|||||
2 |
Platelet-Leukocyte Interactions Mediate Stroke Outcomes Matthew Rondina. |
|||||
3 |
Determinants of Platelet Hyperreactivity with Aging Jorge DiPaola. |
|||||
RISK AND BENEFITS OF COMBINATION ANTITHROMBOTIC THERAPY IN CAD: WHEN LESS IS MORE Chair/Organizer: Eric Grabowski
Virtual Room 1 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
|||||
1 |
UPDATE ON RESPONSIVENESS TO ANTIPLATELET THERAPY J. Eduardo Bahena-Lopez. Affiliation: National Institute of Cardiology of Mexico |
|||||
2 |
Is There Any Role For Aspirin In The Treatment Or Prevention Of Venous Thrombosis? David Garcia. University of Washington |
|||||
3 |
Stable CAD And Peripheral Arterial Disease: When Should An Anticoagulant Be Considered For Added Protection Renato Lopes. Duke Clinical Research Institute |
|||||
6:00 - 7:00 PM
|
ON-DEMAND SYMPOSIUM: A BREAKTHROUGH IN ATTP TREATMENT: NOW RECOMMENDED BY THE ISTH GUIDELINES
Virtual Room 1 Sponsored By: Sanofi Genzyme The program will provide an overview of acquired thrombotic thrombocytopenic purpura (aTTP) – a rare, life-threatening, auto-immune disease - and the urgency for rapid diagnosis and treatment. The program will then review the recently published ISTH Guidelines on the diagnosis and treatment of aTTP with a focus on the first and only FDA-approved therapy indicated for adults with aTTP. View full prescribing information for an aTTP product here. MAT-US-2019445-v1.0-09/2020 Click here to submit a question. |
||||
| |
ON-DEMAND SYMPOSIUM: HEMOPHILIA A WITHOUT INHIBITORS: PERSONALIZING THERAPY WITH FACTOR VIII PROPHYLAXIS
Virtual Room 3 Sponsored By: Takeda Pharmaceuticals U.S.A., Inc. Clinicians and patients face challenges in current factor VIII replacement therapy, including the frequency of intravenous factor infusions as well as patient adherence. Lack of adherence to prophylactic treatment leads to increased frequency of bleeds and development of hemophilic arthropathy. New treatment options for patients with hemophilia A offer the potential for more effective and convenient treatments, including new and emerging prolonged half-life clotting factors such as FVIII-Fc and pegylated FVIII, that offer a therapeutic option with decreased bleeding rates and less frequent infusions. In this case-based, one-hour pre-recorded virtual symposium, renowned hemophilia experts Michael Callaghan, MD, Miguel Escobar, MD, and Guy Young, MD, provide their perspectives on recent changes in Factor VIII replacement therapy management that are improving patient care. Click here to submit a question about the symposium. Continuing Education Information: In accordance with ACCME, ANCC, and ACPE requirements, activities are certified for credit through CCO. This program will be certified by CCO for AMA PRA Category 1 Credit™, ACPE contact hours, and ANCC contact hours. Please click on the following link to obtain CME. https://www.clinicaloptions.com/event/HemophiliaChicago2020Eval Questions? Email [email protected] |
||||
| |
ON-DEMAND SYMPOSIUM: MORE THAN ABRS (ANNUAL BLEED RATES): HCP AND PATIENT PERSPECTIVES IN AN EVOLVING HEMOPHILIA TREATMENT LANDSCAPE
Virtual Room 2 Sponsored By: Sanofi Genzyme, Intended for US Healthcare Professionals Only The use of factor replacement therapy in the treatment of hemophilia has come a long way and continues to change. Join us for a discussion looking beyond ABRs and at how this evolution impacts how we think about treatment approaches for different patients. Topics will include HCP and patient perspectives on how clinical data translate into real world, innovative approaches to patient engagement, with an emphasis on bleed and joint bleed protection. Please see important safety information throughout this presentation and full prescribing information at the links provided below. Full Prescribing Information for a Hemophilia A treatment Full Prescribing Information for a Hemophilia B treatment MAT-US-2021089 v1.0 10/2020 Click here to submit a question. |
||||
6:15 - 7:00 PM
|
THSNA NETWORKING HAPPY HOUR: THE CHANGING FACE OF ANTICOAGULATION SERVICES. Chair/Organizer: Arthur Allen
Virtual Room 4 Open forum to discuss changes AC service staff members are facing with the decline in warfarin utilization and increased use of DOACs. Focus on role as expert consultants, DOAC oversight, and anticoagulation stewardship. |
||||
7:00 - 8:00 PM
|
BLEEDING DISORDER IMPACT
Virtual Room 4 |
||||
Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD: a report from the Universal Data Collection surveillance project. Brandi Dupervil 1, Karon Abe1, Sarah O'Brien2, Meredith Oakley1, Roshni Kulkarni3, Vanessa Byams1, Mike Soucie1. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.2The Research Institute a Nationwide Children, Columbus, OH, USA.3Centers for Bleeding and Clotting Disorders, Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA |
||||||
Heavy Menstrual Bleeding Impact on Mental Health in Adolescent and Young Adult Women With Bleeding Disorders Mary McGrath1, Elisabeth Quint2, Angela Weyand1. 1Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.2Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA |
||||||
Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study Ellis J Neufeld1, Ri J Liesner2, on behalf of the GENA-15 Study Group1. 1St. Jude Children, Memphis, TN, USA.2Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom |
||||||
Socially Vulnerable Youth with Bleeding Disorders: Piloting Novel Interventions in Children’s Healthcare (NICH) David V Wagner, Michael Recht, Susan Lattimore, Kristina Haley, Erin Stang, Kim Spiro, Michael A Harris. Oregon Health and Science University, Portland, OR, USA |
||||||
| |
BLEEDING DISORDER THERAPY AND OUTCOMES
Virtual Room 5 |
||||
Increased Hemophilia-related Distress is Associated with Reduced Adherence to Factor Replacement Therapy. Sara A. Guasch1, Janet Figueroa 1, Vaughn Barry1, Shanna Mattis1, Tyler W. Buckner2, Duc Q. Tran1, Stephanie Whitten 1, Christine L. Kempton 1. 1Emory University, Atlanta, GA, USA.2University of Colorado, Aurora, CO, USA |
||||||
Patients with G-HSD/hEDS evaluated at HTCs have similar co-morbidites to those in the general population Rohith Jesudas1, Christopher Eberlin2, Sweta Gupta3, Amit Soni4, Diane Neugent4, Nina Hwang4, Vanessa Salinas4, Nicole Crook4, Ateefa Chaudhury4, Christina Laukaitis5. 1Bleeding and clotting disorders institute, Peoria, IL, USA.2University of Illinois College of Medicine in Peoria, Peoria, IL, USA.3Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.4Center for Inherited Blood Disorders, Orange, CA, USA.5University of Arizona, Tucson, AZ, USA |
||||||
Hematology Provider Attitudes and Practices Regarding IUD Insertion in Adolescents with Heavy Menstrual Bleeding with and without Bleeding Disorders Allison Wheeler1, Katherine O'Flynn O'Brien2, Claudia Borzutzky3, Peter Kouides4, Oluyemisi Adeyemi-Fowode2. 1Vanderbilt University Medical Center, Nashville, TN, USA.2Texas Children's Hospital, Houston, TX, USA.3Children's Hospital of Los Angeles, Los Angeles, CA, USA.4Mary M Gooley Hemophilia Treatment Center, Rochester, NY, USA |
||||||
| |
INHERITED AND ACQUIRED BLEEDING DISORDERS
Virtual Room 6 |
||||
Second-Line Therapy with Fostamatinib in Patients with Immune Thrombocytopenia (ITP) Ralph Boccia1, Waleed Ghanima2, Quentin Hill3, Michelle Sholzberg4, Michael D Tarantino5, Darla Liles6, Yuliya Kreychman7, Robert P Numerof7, Sonia Souza7, Leslie Todd7, Sandra Tong7, James B Bussel8. 1Center for Cancer and Blood Disorders, Bethesda, MD, USA.2Department of Research, Ostfold Hospital Trust, Sarpsborg and Department of Hematology, Institute of Clinical Medicine, Sarpsborg, Norway.3Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.4Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada.5The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA.6East Carolina University Brody School of Medicine, Greenville, NC, USA.7Rigel Pharmaceuticals, Inc., South San Francisco, CA, USA.8New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA |
||||||
Screening for factor IX Padua (R338L) in pediatric thrombosis patients Benjamin J Samelson-Jones1, 2, 3, James F. Jarrett III1, Leslie J. Raffini1, 2, Valder R. Arruda1, 2, 3. 1The Children's Hospital of Philadelphia, Philadelphia, PA, USA.2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.3Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA |
||||||
Assessment of Rare Bleeding Disorders in Adolescent Females with Unexplained Bleeding Ruchika Sharma1, 2, Seema Menon2, Michelle Dobratz1, Bridgit Hansen1, Victoria Johnson1, Veronica Flood1, 2. 1Versiti Blood Center of Wisconsin, Milwaukee, WI, USA.2Medical College of Wisconsin, Milwaukee, WI, USA |
||||||
| |
THROMBOSIS: CLINICAL
Virtual Room 7 |
||||
Development of a Brief Screening Tool for Emotional Harm Associated with Venous Thromboembolism Keith S. Keddington1, Aubrey E. Jones1, Michael Feehan2, Daniel M. Witt1. 1University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA.2Kantar LLC, Boston, MA, USA |
||||||
Venous Thromboembolism in Patients with Uterine Fibroids Hira Latif1, Valentina Baez Sosa1, Stephen J. Fernandez2, Nicholas D. Hazen1, James K. Robinson1, Vadim Morozov1, Kelly W. Fitzpatrick1. 1MedStar Washington Hospital Center, Washington, DC, USA.2MedStar Health Research Institute, Washington, DC, USA |
||||||
Racial disparities across age groups in Illinois hospital admissions for pulmonary embolism Karlyn Martin1, Megan McCabe2, Joseph Feinglass3, Sadiya Khan2. 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.3Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA |
||||||
Choice of anticoagulation therapy and persistence among patients with atrial fibrillation following a shared decision-making encounter Jeff Nagge1, Sherilyn Houle1, Eunice Chan1, Kristen Stypa1, Ai-Leng Foong1, Ryan McKee2. 1University of Waterloo, Kitchener, ON, Canada.2Centre for Family Medicine, Kitchener, ON, Canada |
||||||
7:00 - 7:45 PM
|
VIRTUAL POSTERS - INFORMATIONAL ONLY
Virtual Room 3 Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the “Ask a Question” option. Note that all questions may not receive a response. |
||||
| |
VIRTUAL POSTERS - PATHOPHYSIOLOGY OF THROMBOSIS
Virtual Room 2 Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the “Ask a Question” option. Note that all questions may not receive a response. |
||||